

## **Symposium 29: Recent Advances in TB Drug Development**

November 12, 2007

9:00-11:15 a.m.

Room 2.60

38th Union World Conference on Lung Health

*Conference registration required*

Standard TB treatment regimens for active disease are resource-intensive; make adherence difficult due to their complexity and length; are ineffective against resistant strains; and are difficult to co-administer safely with anti-retroviral therapy. For the first time in forty years, there is a significant pipeline of TB drug candidates, representing concerted efforts from a variety of public and private sector organisations and emerging R&D centres in endemic countries.

The objectives of this symposium are to review progress in the global TB drug pipeline and present efforts underway to develop surrogate markers to speed development and registration of new TB drug candidates

### **Chairpersons:**

- Ann Ginsberg, Global Alliance for TB Drug Development
- Charles Mgone, European & Developing Countries Clinical Trials Partnership

### **Presentations:**

- ***Key issues in TB drug development; A regulatory perspective***  
Leonard Sacks, U.S. Food and Drug Administration
- ***Overview of the global TB drug pipeline***  
Christo van Niekerk, Global Alliance for TB Drug Development
- ***The quest for TB biomarkers discovery***  
Shreemanta K. Parida, Max-Planck Institute for Infection Biology
- ***Update on the development of OPC67683***  
Larry Geiter, Otsuka Pharmaceutical Development  
& Commercialization, Inc.
- ***Phase II study: The effect on 2-month culture conversion of substitution of moxifloxacin for isoniazid in TB treatment***  
Susan Dorman, Johns Hopkins School of Medicine